Larry L Hillblom Foundation Inc.

The Larry L. Hillblom Foundation operates as one of California's most focused private health research funders, directing essentially all of its approximately $7–10M in annual giving toward two scientific areas: diabetes mellitus/metabolic syndrome and age-related neurodegeneration and vision disorders. Founded in 1996 through the estate of Larry Hillblom — co-founder of DHL Worldwide Express — the foundation has distributed roughly $150 million across 317 research grants, establishing deep, recurring relationships with the University of California system and leading California research institutes.

The foundation's giving philosophy is institution-first and relationship-oriented. The UC system dominates the grantee roster: UC system campuses collectively account for the majority of research dollar volume, led by UC San Diego ($3.5M across 5 grants), the Regents broadly ($12.6M across 10 grants), UC Santa Barbara ($1.2M), UCSF ($500K plus additional Fresno campus support), UC Berkeley ($260K), and UC Irvine ($260K). Independent research institutes with national reputations — Salk ($2.8M), Sanford-Burnham ($1.6M), J. Craig Venter Institute ($1.5M), Buck Institute for Research on Aging ($1.3M), Gladstone Institutes ($120K), Scripps ($210K) — form a secondary tier. Stanford ($1.4M) and Caltech ($205K) represent elite private universities in the portfolio.

The application path differs meaningfully by career stage. Fellowship grants (up to $75K/year, 3 years) target post-doctoral researchers within 3 years of doctorate completion. Start-Up grants (up to $120K/year, 3 years) are designed for early-career faculty within 3 years of first appointment who can demonstrate 80% research commitment and institutional backing via a specific commitment letter. The Network grant program — the flagship mechanism for established PIs at up to $600K/year for 4 years — is currently paused for new applicants as of the 2026 cycle. This means the only viable entry points today are the Fellowship and Start-Up tracks.

First-time applicants should understand that LLHF does not fund overhead-heavy programs, general operations, or community health initiatives. Research must employ genetic, molecular, cellular, or metabolic approaches — clinical epidemiology and health services research are out of scope. Applications are reviewed by two specialized advisory boards: a Diabetes Advisory Board with representation from UCSF, University of Vermont, and Yale; and an Aging Advisory Board drawing from Albert Einstein College of Medicine, UCLA, and UCSF's Memory and Aging Center. Framing your research in language resonant with these institutions' published work can strengthen reviewer alignment.

LLHF's financial profile reflects a well-endowed operating foundation with disciplined endowment management. Assets have grown from $122.3M (FY2012) to $152.5M (FY2024), notwithstanding distribution years and market volatility. Annual total giving has ranged from $4.98M (FY2013) to $11.5M (FY2014) across the 10 fiscal years with available data. Recent giving: $9.6M (FY2019), $7.7M (FY2020), $8.7M (FY2021), $7.2M (FY2022), $9.6M (FY2023). The FY2024 record shows $8.2M in revenue but no giving figure yet filed, suggesting a consistent ~$7–10M annual distribution range.

The grantee database reveals a bimodal distribution. Research grants to universities and institutes are large — the top recipient, the UC Regents, received $12.6M across 10 grants (average $1.26M per grant). UC San Diego averaged $696K per grant; Salk Institute $557K; Stanford $278K; Buck Institute $252K; J. Craig Venter Institute $300K. A second, distinct tier of smaller community grants to Sonoma County and Kingsburg-area nonprofits (churches, schools, social services, animal rescue organizations) runs $2,000–$80,000. These community disbursements reflect the founder's personal ties to specific California communities but represent a separate philanthropic track from the medical research programs.

Current program funding envelopes: - Fellowship Grant: up to $75,000/year × 3 years = maximum $225,000 total (non-renewable) - Start-Up Grant: up to $120,000/year × 3 years = maximum $360,000 total (non-renewable) - Network Grant: up to $600,000/year × 4 years = maximum $2.4M total (currently paused for new applicants)

All programs cap indirect costs at 10% of the total budget (included, not added). This below-market indirect rate substantially reduces the appeal to institutions accustomed to 40–60% F&A recovery. Budget line-item caps for Start-Up grants: $25,000/year supplies, $5,000/year equipment, $2,500/year travel. Geographic concentration is extreme: approximately 95% of grants go to California recipients. The foundation's stated preference for UC research programs within California has remained consistent across the full data period.

The following table compares LLHF to four peer foundations with comparable asset bases and health research missions:

LLHF's most distinctive competitive advantage among these peers is its open application process with publicly posted deadlines — it is the only foundation in this comparison that accepts unsolicited applications with a clear annual submission window. The Glenn Foundation for Medical Research pursues the closest scientific parallel (aging biology, longevity research) but operates almost entirely through invited collaborations with pre-selected investigators, making it functionally inaccessible for most new applicants. Walther and Regenstrief are geographically restricted to Indiana, and the Harvey W Peters Foundation has minimal public-facing application infrastructure. For California-based early-career diabetes and aging researchers, LLHF represents a rare combination of open access, meaningful award sizes, and scientific alignment.

The most consequential recent development is LLHF's decision to pause new Network Grant applications beginning with the 2026 funding cycle. The foundation cited a desire to 'devote maximum resources toward Fellowship and Startup grants' amid what it characterized as uncertain times in medical research funding — widely interpreted as a response to disruptions in NIH and federal grant pipelines under the current political climate. The Network Grant had been the foundation's flagship mechanism for established PIs, offering up to $600,000 annually for four years. Its pause represents a meaningful reallocation of capital toward earlier-career scientists.

On the programmatic side, the 21st Annual Scientific Meeting convened October 20–21, 2025, in Rancho Mirage, CA. The prior year's 20th edition took place at the Monterey Plaza Hotel & Spa, Cannery Row, Monterey (September 2024). These annual meetings are central to the foundation's community model — active grantees present research findings and interact directly with program staff and advisory board members.

In November 2025, LLHF announced its 2025 Distinguished Research Scientists cohort — the annual recognition program honoring exemplary grantee performance. This program has been consistently operated since at least 2022.

Leadership appears stable: Joseph W. Waechter serves as Chairman and President; Dave Pier as Executive Director; David R. Jones as CFO (compensation ~$187,900); Grant A. Anderson as Vice President. Board directors include Ingrid Hermreck, Ida O'Brien, and Hannah Anderson-Ortega. No leadership transitions have been publicly announced.

Timing is the single most underestimated factor. The application portal opens January 1 and closes January 31 at 5:00 PM PST — a 30-day window. But the bottleneck is not writing the proposal; it is securing the institutional commitment letter. This letter must be signed by your institution's sponsored programs office or equivalent authority, and must specifically document: dedicated office space, administrative support, and a teaching load capped at one day per week in Year 1. At major UC campuses and research institutes, administrative processing can take 3–6 weeks. Begin the letter request in November to avoid missing the deadline.

Match the scientific framing precisely. LLHF funds two categories and only two: (1) Diabetes Mellitus/Metabolic Syndrome and its complications, including studies of normal glucose metabolism; and (2) age-related chronic or degenerative disorders of the brain or vision, including studies of healthy aging processes. Brain and vision are explicitly the primary aging focus. Research must employ genetic, molecular, cellular, or metabolic approaches. Health services, epidemiological, or behavioral science proposals will not succeed regardless of merit.

The lay summary drives board-level decisions. The one-page lay summary is read by directors and board members without scientific training. Treat it as your pitch document, not a formality. Lead with the patient problem, describe your approach in accessible language, and articulate what success looks like clinically. Reviewers who favor funding a proposal often cite the lay summary as the document that made the case.

Leverage UC system relationships actively. The foundation has awarded more than $17M to UC campuses and has deep familiarity with UC departmental cultures. Department chairs at UCSD, UCSF, Berkeley, and UCLA who have prior LLHF engagement can be valuable connectors. If your institution has an established track record with LLHF, make that explicit in your application narrative.

For Fellowship applicants: mentor selection is critical. The foundation will evaluate your mentor's CV and track record carefully. Mentors who are current or past LLHF grantees, or who are recognized by the foundation's advisory boards, provide a material credibility signal. Two strong recommendation letters (including mentor) are required.

Never include pre-publication work. LLHF reviewers check publication lists for papers under review or not yet published — inclusion is an explicit red flag and eligibility concern. Only include published, peer-reviewed work.